--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) cordially invites you to attend two investor receptions in conjunction with the 2010 ASCO Annual Meeting:
• Saturday, June 5, 2010 - “XL184: GBM study results and development update”
• Monday, June 7, 2010 - “XL184: MTC and Randomized Discontinuation Trial study results and development updates”
Both receptions will be held in the Honore Ballroom at the Palmer House Hilton Hotel, 17 East Monroe Street, Chicago, IL 60603 at 6:00 p.m. CT.
Please RSVP by visiting the following link: http://www.exelixis.com/form_asco_2010_investor.shtml
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com.
